title: Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice.
abstract: Interleukin 23 receptor expressing IL-17 producing T cells have been shown to be important in the development of murine lupus. The usefulness of IL-23 inhibition in ameliorating lupus nephritis is unknown. We hypothesized that inhibition of IL-23 will ameliorate nephritis in lupus-prone mice. To this end, we treated MRL/lpr lupus-prone mice for 6 weeks with a rat anti-IL-23p19 antibody, which resulted in delaying the onset of nephritis without affecting the production of anti-dsDNA antibodies. The effect of the treatment was hampered by the production of murine anti-rat IgG antibodies. The amelioration of murine lupus by IL-23 inhibition strengthens the rationale for targeting IL-23 in patients with systemic lupus erythematosus.
authors.affiliation: Division of Rheumatology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, CLS-936, Boston, MA 02215, USA. vkyttari@bidmc.harvard.edu
authors.forename: Vasileios C
authors.initials: VC
authors.lastname: Kyttaris
authors.forename: Ourania
authors.initials: O
authors.lastname: Kampagianni
authors.forename: George C
authors.initials: GC
authors.lastname: Tsokos
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage; D006801:Humans; D053759:Interleukin-23 / Q000037:antagonists & inhibitors / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D008181:Lupus Nephritis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D051379:Mice; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D053759:Interleukin-23; C048844:anti-IgG